Eva Lion, Ph.D.
Affiliations: | 2011 | Universiteit Antwerpen (Belgium) |
Area:
Immunology, Rehabilitation and Therapy, OncologyGoogle:
"Eva Lion"Parents
Sign in to add mentor| Viggo V. Tendeloo | grad student | 2011 | Universiteit Antwerpen (Belgium) | |
| (The added value of natural killer cells in immunotherapy for leukemia.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Berneman ZN, De Laere M, Germonpré P, et al. (2025) WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome. Journal of Hematology & Oncology. 18: 9 |
| Gielis S, Flumens D, van der Heijden S, et al. (2024) Analysis of Wilms' tumor protein 1 specific TCR repertoire in AML patients uncovers higher diversity in patients in remission than in relapsed. Annals of Hematology |
| Van den Bossche J, De Laere M, Deschepper K, et al. (2024) Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study. Plos One. 19: e0307204 |
| Van Genechten T, De Laere M, Van den Bossche J, et al. (2024) Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium. Bmj Open. 14: e077613 |
| van der Heijden S, Flumens D, Versteven M, et al. (2023) In vitro expansion of Wilms' tumor protein 1 epitope-specific primary T cells from healthy human peripheral blood mononuclear cells. Star Protocols. 4: 102053 |
| Erdem R, De Coster I, Withanage K, et al. (2023) Safety, tolerability, and immunogenicity of inactivated poliovirus vaccine with or without E.coli double mutant heat-labile toxin (dmLT) adjuvant in healthy adults; a phase 1 randomized study. Vaccine |
| Debie Y, Van Audenaerde JRM, Vandamme T, et al. (2022) Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Roex G, Campillo-Davo D, Flumens D, et al. (2022) Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. Journal of Translational Medicine. 20: 124 |
| Versteven M, Flumens D, Campillo-Davó D, et al. (2022) Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by Silencing of Programmed-Death Ligands. Frontiers in Immunology. 13: 734256 |
| Elias G, Meysman P, Bartholomeus E, et al. (2022) Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon hepatitis B vaccination. Elife. 11 |